| Quarterly Financials | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 268 | 206 | 411 | 361 | 363 | 478 | 417 | 398 | 388 | 501 | 588 | 569 | 581 | 609 | 655 | 609 | 638 | 693 | 782 | 790 | 812 | 879 | 965 |
| Expenses | 203 | 165 | 268 | 268 | 258 | 330 | 283 | 264 | 259 | 358 | 412 | 411 | 413 | 449 | 475 | 459 | 475 | 509 | 559 | 585 | 599 | 679 | 757 |
| EBITDA | 65 | 40 | 143 | 93 | 105 | 148 | 134 | 134 | 129 | 143 | 177 | 158 | 168 | 160 | 180 | 150 | 163 | 184 | 223 | 205 | 213 | 200 | 208 |
| Operating Profit % | 24 % | 18 % | 34 % | 26 % | 28 % | 30 % | 31 % | 33 % | 31 % | 28 % | 27 % | 27 % | 28 % | 26 % | 27 % | 24 % | 25 % | 26 % | 28 % | 24 % | 25 % | 22 % | 21 % |
| Depreciation | 17 | 17 | 16 | 20 | 17 | 17 | 18 | 19 | 19 | 29 | 31 | 33 | 35 | 32 | 33 | 35 | 46 | 39 | 41 | 45 | 53 | 53 | 66 |
| Interest | 10 | 9 | 7 | 9 | 7 | 6 | 3 | 3 | 4 | 6 | 8 | 12 | 5 | 9 | 9 | 12 | 16 | 18 | 20 | 26 | 27 | 33 | 45 |
| Profit Before Tax | 38 | 14 | 120 | 65 | 81 | 125 | 113 | 112 | 107 | 107 | 138 | 113 | 127 | 119 | 139 | 102 | 100 | 127 | 162 | 135 | 134 | 114 | 97 |
| Tax | 10 | 5 | 29 | 17 | 22 | 33 | 29 | 28 | 24 | 28 | 31 | 31 | 29 | 32 | 37 | 26 | 29 | 32 | 42 | 42 | 28 | 29 | 25 |
| Net Profit | 28 | 9 | 90 | 48 | 59 | 92 | 84 | 84 | 83 | 79 | 106 | 82 | 99 | 87 | 101 | 77 | 72 | 95 | 121 | 93 | 106 | 85 | 72 |
| EPS in ₹ | 3.72 | 1.49 | 11.21 | 6.55 | 7.72 | 11.48 | 10.34 | 10.14 | 10.08 | 8.74 | 12.14 | 9.49 | 11.65 | 10.10 | 11.50 | 8.98 | 8.18 | 10.82 | 2.68 | 2.22 | 2.54 | 1.96 | 1.67 |
Krishna Institute of Medical Sciences
Krishna Institute of Medical Sciences
669.90
-8.55
(-1.26%)
Key Fundamentals
Market Cap
26,805.31 Cr
EPS
9.61
PE Ratio
75.73
Dividend Yield
0.00 %
Industry
Healthcare Services 52 Week High
798.40
52 Week Low
474.05
PB Ratio
11.87
Debt to Equity
0.99
Sector
Hospitals Analyst Rating and Forecast
- By Refinitiv from11 analysts
Actual
Company News
View All News
KIMS Hospitals reported Q2 FY26 revenue of INR 965 crores with 23.3% year-on-year growth, but EBITDA declined 6.7% to INR 208 crores and PAT dropped to INR 72 crores from INR 121 crores last year due to losses from newly commissioned hospitals. The company expects new facilities in Thane, Bangalore, and Nashik to achieve EBITDA breakeven within 12 months of commissioning, with management confident about ramp-up trajectory and 20% CGHS price hike benefits flowing from Q4.
Krishna Institute of Medical Sciences Limited reported consolidated revenue of INR 9,649 million for Q2FY26, marking a 23.3% year-on-year growth and 9.8% quarter-on-quarter increase. However, EBITDA declined 6.7% year-on-year to INR 2,082 million, with margins compressing to 21.6% from 28.5% in the previous year. Profit after tax dropped to INR 720 million from INR 1,207 million in Q2FY25. The company corrected data errors in its investor presentation related to bed numbers and occupancy percentages across multiple pages. KIMS operates across Telangana, Andhra Pradesh, Maharashtra, Karnataka and Kerala with a total bed capacity of 6,114 beds. The hospital chain achieved operational highlights including 15.3% growth in inpatient volume and 25.1% increase in outpatient volume. Average revenue per occupied bed grew 9.8% year-on-year to INR 42,016. The company has expansion plans including new facilities in Bangalore, Ongole, Anantapur, Kondapur and Rajahmundry with expected investments ranging from INR 40-350 crores.
KIMS Plans Double-Digit Revenue Growth Through Bengaluru Expansion and Tier-2 Hospital Development
Nov 11, 2025
Nov 11, 2025KIMS outlined a strong growth strategy centered on expanding its healthcare network and optimizing operations. The company is establishing a new 700+ bed facility in Bengaluru and expanding tier-2 hospitals in Andhra Pradesh and Telangana. KIMS targets double-digit revenue growth by increasing Average Revenue Per Occupied Bed (ARPOB) and optimizing its specialty mix. The growth plan emphasizes operational leverage, retaining medical talent, and pursuing strategic acquisitions to strengthen market leadership position.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,168.40 | #1 1,13,596.10 | 83.67 | 7,184.10 | #1 28.65 | 1,076 | #1 74.34 | 52.42 | |
7,385.50 | 1,06,192.16 | 61.72 | #1 21,994.30 | 14.76 | #1 1,505 | 24.84 | 34.25 | |
924.50 | 69,795.88 | 68.04 | 7,849.70 | 13.25 | 809 | 70.27 | 31.55 | |
1,954.40 | 39,940.28 | 48.80 | 5,575.00 | 12.29 | 790 | 30.03 | 61.94 | |
655.65 | 33,970.61 | 94.45 | 4,286.70 | 15.12 | 337 | 14.65 | 46.21 | |
1,242.80 | 33,405.27 | 58.06 | 3,771.40 | 12.59 | 481 | 21.10 | 48.12 | |
669.90 | #7 26,805.31 | #7 75.73 | #7 3,067.00 | #3 21.98 | #6 415 | #10 -40.35 | 43.04 | |
494.40 | 15,630.87 | 107.45 | 1,757.00 | 27.64 | 110 | 71.36 | 49.71 | |
6,065.00 | 15,477.38 | #1 28.77 | 599.90 | 11.69 | 58 | 16.17 | 34.63 | |
1,337.00 | 13,578.46 | 53.31 | 1,566.90 | 17.46 | 244 | -4.30 | 48.47 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
21.98 %
Net Income Growth
23.49 %
Cash Flow Change
11.65 %
ROE
6.85 %
ROCE
-11.21 %
EBITDA Margin (Avg.)
2.27 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 958 | 1,118 | 1,196 | 1,436 | 1,907 | 2,941 | 3,852 | 5,736 |
| Fixed Assets | 755 | 863 | 916 | 931 | 1,005 | 1,766 | 2,434 | 3,349 |
| Current Assets | 156 | 174 | 220 | 451 | 393 | 478 | 547 | 697 |
| Capital Work in Progress | 0 | 0 | 2 | 9 | 21 | 477 | 600 | 1,214 |
| Investments | 0 | 0 | 0 | 0 | 333 | 68 | 157 | 99 |
| Other Assets | 203 | 254 | 278 | 496 | 549 | 630 | 660 | 1,075 |
| Total Liabilities | 958 | 1,118 | 1,196 | 1,436 | 1,907 | 2,941 | 3,852 | 5,736 |
| Current Liabilities | 749 | 201 | 219 | 278 | 215 | 297 | 452 | 836 |
| Non Current Liabilities | 347 | 351 | 366 | 282 | 282 | 707 | 1,307 | 2,481 |
| Total Equity | -138 | 566 | 611 | 876 | 1,411 | 1,938 | 2,093 | 2,419 |
| Reserve & Surplus | -209 | 466 | 523 | 786 | 1,307 | 1,590 | 1,748 | 2,058 |
| Share Capital | 50 | 75 | 75 | 78 | 80 | 80 | 80 | 80 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 5 | -11 | 5 | 3 | -3 | 33 | 12 | -27 | 36 | -15 | 9 |
| Investing Activities | -71 | -41 | -100 | -64 | -110 | -125 | -354 | -412 | -416 | -753 | -1,116 |
| Operating Activities | 64 | 95 | 82 | 106 | 134 | 202 | 356 | 324 | 432 | 521 | 582 |
| Financing Activities | 12 | -66 | 24 | -39 | -27 | -44 | 10 | 61 | 20 | 217 | 543 |
Share Holding
| % Holding | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 38.84 % | 38.84 % | 38.84 % | 38.84 % | 38.84 % | 38.84 % | 38.84 % | 38.84 % | 38.84 % | 38.84 % | 38.82 % | 38.82 % | 38.82 % | 38.82 % | 38.82 % | 38.82 % | 34.11 % | 34.11 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 8.61 % | 8.61 % | 0.00 % | 14.25 % | 0.00 % | 16.73 % | 17.84 % | 15.85 % | 15.68 % | 15.45 % | 15.54 % | 15.03 % |
| DIIs | 13.81 % | 16.11 % | 18.35 % | 18.49 % | 20.46 % | 27.98 % | 28.32 % | 29.76 % | 33.03 % | 34.80 % | 31.63 % | 33.13 % | 32.12 % | 32.30 % | 32.05 % | 31.95 % | 31.66 % | 32.12 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 13.14 % | 14.23 % | 13.38 % | 12.88 % | 11.81 % | 11.50 % | 11.32 % | 11.10 % | 11.22 % | 11.15 % | 10.84 % | 10.73 % | 10.61 % | 10.55 % | 10.97 % | 11.24 % | 11.58 % | 11.72 % |
| Others | 34.21 % | 30.82 % | 29.42 % | 29.79 % | 28.88 % | 21.68 % | 12.92 % | 11.69 % | 16.91 % | 0.96 % | 18.70 % | 0.59 % | 0.61 % | 2.48 % | 2.48 % | 2.54 % | 7.11 % | 7.03 % |
| No of Share Holders | 0 | 267 | 86,389 | 74,355 | 73,664 | 70,795 | 67,735 | 60,980 | 65,449 | 66,957 | 71,014 | 69,092 | 69,063 | 77,617 | 95,468 | 1,01,895 | 1,08,955 | 1,04,872 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 29 Aug 2024 |  Annual General Meeting | NA | 29 Aug 2024 | 389.93 | 502.38 |
| 28 Jun 2024 |  Split | 2:10 | 13 Sept 2024 | 420.62 | 420.62 |
| 09 Nov 2024 |  Quarterly Result Announcement | NA | 09 Nov 2024 | 520.35 | 570.15 |
| 06 Feb 2025 | Quarterly Result Announcement | NA | 06 Feb 2025 | 606.05 | 649.15 |
| 12 May 2025 | Quarterly Result Announcement | NA | 12 May 2025 | 657.35 | 635.00 |
| 06 Aug 2025 | Quarterly Result Announcement | NA | 06 Aug 2025 | 763.85 | 741.05 |
| 29 Aug 2025 | Annual General Meeting | NA | 29 Aug 2025 | 635.00 | 737.40 |
| 07 Nov 2025 | Quarterly Result Announcement | NA | 07 Nov 2025 | 720.20 | 720.15 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 10, 2025
Nov 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2025
Nov 08, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 07, 2025
Nov 07, 2025Krishna Institute Of Medical Sciences Limited Has Informed The Exchange Regarding Limited Review Reports On Standalone & Consolidated Financials For The Quarter And Half Year Ended September 30 2025Nov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-AcquisitionNov 07, 2025
Nov 07, 2025Results For The Quarter And Half Year Ended 30.09.2025Nov 07, 2025
Nov 07, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On 07Th November 2025Nov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 04, 2025
Nov 04, 2025Announcement U/R 30 Of LODROct 29, 2025
Oct 29, 2025Board Meeting Intimation for The Unaudited (Standalone & Consolidated) Financial Results Of The Company For The 02Nd Quarter And Half-Year Ended September 30 2025.Oct 24, 2025
Oct 24, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Oct 14, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Commencement Of Operations At KIMS Hospital Mahadevapura BengaluruSep 15, 2025
Sep 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 08, 2025
Sep 08, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 01, 2025
Sep 01, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 29, 2025
Aug 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 26, 2025
Aug 26, 2025It Has Come To Attention That The Annexure Containing Additional Information Of The Director Seeking Re-Appointment As Required Under Regulation 36(3) Of The SEBI (LODR) Regulations 2015 And Secretarial Standard On General Meetings (SS-2) Issued By The InAug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
Aug 09, 2025Web-Link Of The Integrated Annual Report For The Financial Year 2024-25Aug 07, 2025
Aug 07, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 07, 2025
Aug 07, 2025Reg. 34 (1) Annual Report.Aug 07, 2025
Aug 07, 2025Notice Convening The 23Rd Annual General MeetingAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 06, 2025
Aug 06, 2025ResultsAug 06, 2025
Aug 06, 2025Board Meeting Outcome for Outcome Of Board Meeting For Q1FY26Aug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 30, 2025
Jul 30, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJul 25, 2025
Jul 25, 2025Board Meeting Intimation for The Approval Of The Unaudited (Standalone & Consolidated) Financial Results Of The Company For The 01St Quarter Ended June 30 2025.Jul 24, 2025
Jul 24, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 12, 2025
Jul 12, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceJul 01, 2025
Jul 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 23, 2025
Jun 23, 2025Closure of Trading WindowJun 23, 2025
Jun 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 21, 2025
Jun 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 20, 2025
Jun 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Jun 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 09, 2025
Jun 09, 2025Mutual Fund Holdings
Invesco India Smallcap Fund Direct - Growth 
Mirae Asset Small Cap Fund Direct-Growth 
TRUSTMF Flexi Cap Fund Direct - Growth 
Union Small Cap Fund Direct-Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
Samco Special Opportunities Fund Direct - Growth 
Axis Value Fund Direct-Growth 
Tata India Pharma & Healthcare Fund Direct-Growth 
Kotak Quant Fund Direct - Growth 
Bandhan Midcap Fund Direct-Growth 
ITI Small Cap Fund Direct-Growth 
Groww Multicap Fund Direct-Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 43.04
ATR(14)
Volatile 19.17
STOCH(9,6)
Neutral 28.88
STOCH RSI(14)
Neutral 40.73
MACD(12,26)
Bearish -1.99
ADX(14)
Weak Trend 22.41
UO(9)
Bearish 57.14
ROC(12)
Downtrend And Accelerating -5.81
WillR(14)
Neutral -68.92
About Krishna Institute of Medical Sciences
Krishna Institute of Medical Sciences Limited (KIMS) is an Indian healthcare company operating 12 multispecialty hospitals under the KIMS Hospitals brand. With over 4,000 beds, KIMS provides tertiary and quaternary healthcare services across more than 40 specialties and super specialties. The company's network includes hospitals in Telangana, Andhra Pradesh, and Maharashtra. KIMS offers medical education programs through affiliations with state medical boards and universities. The company's hospitals are equipped with advanced medical technology, including robotic surgical systems and specialized imaging equipment. KIMS has received various accreditations and awards for its healthcare services and facilities. In recent developments, Sunshine Hospitals became a subsidiary of KIMS in 2022, and the company opened a new gastroenterology unit in Vizag.
Listing Date
28 Jun, 2021(4 Years,
-3 days)
Chairperson NameBhaskara Rao Bollineni
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
